Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.33−0.04 (-9.78%)
Close on Nov 18, 2026Market cap $4.21MP/E –Yield –
Lantern Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Lantern Pharma's operating income for the twelve months ending Sep 30, 2026 was -$16.49M. For fiscal 2025 it was -$17.98M. The highest annual figure on record is -$12.59M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$17.98M | – |
| FY2024 | Dec 31, 2024 | -$22.22M | – |
| FY2023 | Dec 31, 2023 | -$17.88M | – |
| FY2022 | Dec 31, 2022 | -$14.43M | – |
| FY2021 | Dec 31, 2021 | -$12.59M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$5.38M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.35M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.77M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.41M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.29M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$833.42K | – |
See a number that looks wrong?